Madrid.- A team of australian researchers has shown that the ivermectinmedicine , antiparasitic, can kill the coronavirus in 48 hours on testing “in vitro”, according to a study, published in Antiviral Research.
Experts from the University of Monash in Melbourne (Australia) warn that the tests have been conducted in cell cultures and that it is still necessary to conduct tests on people.
A single dose of ivermectin “could stop the growth of the SARS-CoV-2 in a cell culture, removing effectively all of the genetic material of the virus in a period of 48 hours.”
The next step now, according to the university in a press release, “is to determine the human dose correct”, making sure that the required to deal effectively with the virus “in vitro” is a safe level for people.
The use of ivermectin to combat the Covid-19 depends on the preclinical testing and clinical trials, and “finance is urgently needed to advance the work”, adds the note.
This drug approved by the Food and Drug Administration of united States (FDA) also has been shown to be effective in vitro against a wide range of viruses, including HIV, dengue, influenza, and the virus Zika.
The lead author of the study, Kylie Wagstaff, of the University of Monash, explained that they had discovered that “even a single dose could essentially remove all of the viral RNA in 48 hours and even within 24 hours, there was a reduction really significant”.
Wagstaff noted, however, that the evidence for the study will be conducted “in vitro” and that it is necessary to do trials in people.
“In times that we are having a global pandemic and there is not an approved treatment, if we had a compound that was already available all over the world, that could help people before. Realistically -considered by the researcher-, it will be a while before a vaccine is widely available.”
Although it is not known the mechanism by which ivermectin acts on the coronavirus, taking into account its action on other viruses, “is likely to work to stop the virus’s ability to ‘dampen’ the ability of host cells to eliminate it,” said Wagstaff.
The use of this medicine to fight the Covid-19 would depend, according to the scientific, the results of further preclinical testing and, ultimately, in clinical trials, with funding that is urgently needed to continue to advance the work.